Article Per Year (5 Year)
p-Index From 2021 - 2026
2.083
P-Index
This Author published in this journals
All Journal Biomedika Bioscientia Medicina : Journal of Biomedicine and Translational Research Jurnal Health Sains Indian Journal of Forensic Medicine & Toxicology Narra J Bioscientia Medicina : Journal of Biomedicine and Translational Research MEDICINUS
Prasetyadi Mawardi
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health Veterinary

Published : 13 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 13 Documents
Search

 1   2 
Intralesional Mumps, Measles, Rubella (MMR) Vaccine as Therapy for Recurrent Condyloma Acuminata: A Case Report Sambodo, Shelly Lavenia; Prasetyadi Mawardi; Endra Yustin Ellistasari; Ammarilis Murastami
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 10 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i10.1092

Abstract

Background: Condyloma acuminata (CA), a prevalent sexually transmitted infection caused by the human papillomavirus (HPV), presents challenges in treatment due to its high recurrence rate. While various treatment modalities exist, intralesional immunotherapy with the mumps, measles, rubella (MMR) vaccine has shown promise in managing HPV-related conditions. This case report investigates intralesional MMR vaccine in treating recurrent CA. Case presentation: A 24-year-old female presented with recurrent CA lesions on the labia majora and perianal region. Despite prior treatment with trichloroacetic acid (TCA), the lesions had reappeared. Intralesional MMR vaccine injections were administered twice, one month apart, resulting in complete lesion resolution within six weeks of the second injection. No recurrence was observed during a six-month follow-up period, and the patient reported only mild, transient pain at the injection sites. Conclusion: This case report highlights the potential of intralesional MMR vaccine as an effective and well-tolerated treatment option for recurrent CA. Further research is warranted to validate these findings and establish optimal treatment protocols.
Single-Dose Intralesional Bacillus Calmette-Guérin (BCG) Immunotherapy Induces Complete and Sustained Remission of Recalcitrant Anogenital Condylomata: A Mechanistic Case Series Azhar Arrosyid; Prasetyadi Mawardi; Endra Yustin Ellistasari; Ammarilis Murastami
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 10 No. 1 (2026): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v10i1.1472

Abstract

Background: Anogenital condylomata acuminata caused by Human Papillomavirus (HPV) presents a significant therapeutic challenge due to high recurrence rates after conventional cytodestructive therapies. Intralesional immunotherapy aims to induce a host-mediated immune response, offering a promising alternative. This report investigates the efficacy, safety, and immunological rationale of a novel, single-dose Bacillus Calmette-Guérin (BCG) protocol in an immunologically primed population. Methods: In this prospective case series, three immunocompetent patients with extensive, therapy-refractory anogenital condylomata were enrolled. Following a standardized protocol, each patient received a single, calculated intralesional injection of BCG vaccine into the largest index lesion. The primary outcome was complete clinical and dermoscopic clearance. Patients were evaluated at regular intervals for efficacy and safety over a 12-month follow-up period. Result: All three patients achieved complete clinical and dermoscopic clearance of both the injected and distant, untreated lesions within a rapid timeframe of 6 to 10 weeks. The treatment was well-tolerated, with adverse events limited to anticipated and transient local inflammatory reactions. No recurrences were documented in any patient during the 12-month follow-up period. Conclusion: Single-dose intralesional BCG immunotherapy appears to be a highly effective, durable, and safe therapeutic strategy for recalcitrant anogenital condylomata. The observed pan-lesional clearance strongly suggests the induction of a systemic, cell-mediated anti-HPV immune response. These compelling preliminary findings provide a strong rationale for validation through larger, randomized controlled trials.
Determinant of recovery, recurrence and recurrence-free interval of condyloma acuminata: A five-year cross-sectional data from a provincial referral hospital in Indonesia Prasetyadi Mawardi; Maulana, Muhammad I.; Ellistasari, Endra Y.; Primisawitri, Pratiwi P.; Purnamasari, Rina
Narra J Vol. 6 No. 1 (2026): April 2026
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v6i1.3069

Abstract

Condyloma acuminata is a common sexually transmitted disease caused by human papillomavirus infection and is characterized by frequent recurrence despite available therapies. This study evaluated recovery, recurrence, and recurrence-free interval across therapeutic modalities among condyloma acuminata outpatients at Dr. Moewardi Regional General Hospital, Surakarta, Indonesia, from January 2020 to December 2024. Using a cross-sectional analysis of medical records, 132 eligible patients were included and analyzed with bivariate tests. Treatment modality was not significantly associated with recovery (p=0.157), although recovery was highest with trichloroacetic acid (71.2%), followed by excision (66.7%), combination therapy (trichloroacetic acid + cryotherapy) (64.7%), and cryotherapy alone (33.3%). In bivariate analysis, type of therapy (p=0.025) as well as type of condyloma (p<0.001), sexual orientation (p=0.019), and HIV status were associated with recurrence, with the highest recurrence observed after excision (42.4%) and the lowest after cryotherapy alone (11.1%). Mean recurrence-free interval varied across modalities (cryotherapy 8.00±0.00; trichloroacetic acid (TCA) 15.92±28.49; excision 18.93±13.64; combination therapy 27.50±36.67 weeks), with the longest interval observed in the combination group. However, statistical analysis revealed that only types of condyloma, sexual orientation, and HIV status were associated with the mean recurrence time. Overall, recovery and recurrence patterns differed descriptively across treatment modalities, with excision showing the highest recurrence and cryotherapy alone the lowest. Recurrence outcomes varied according to treatment modality; however, no significant association was observed between therapy type and recurrence-free interval.
Co-Authors Agung Triana Hartati Alfina Rahma Ambar Mudigdo Ambar Mudigdo Ammarilis Murastami Anggana Rafika Paramitasari Azhar Arrosyid Danu Yuliarto Eka Devinta Novi Diana Ellistasari, Endra Y. Elok Nurfaiqoh Endra Yustin Endra Yustin Ellistasari Febrianto, Bobby Fitri Kasmitasari Frieda Harijono Kariosentono Imroatul Ulya Indah Julianto Maulana, Muhammad I. Minna Hasniah Muhammad Eko Irawanto Niluh Widjayanti Primisawitri, Pratiwi P. Purnamasari, Rina Ratih Pramuningtyas Reti Anggraeni Shelly Lavenia Sambodo Susanti Rosmala Dewi Wibisono Nugraha